Excellent Packaging Engineering - Bosch Machine Honoured with Red Dot Award
![](/46/pdcnewsitem/03/43/92/3aZOyddwmF9F38I.jpg)
For the first time, Bosch Packaging Technology has received the internationally renowned “Red Dot Award” from the Design Zentrum Nordrhein-Westfalen in the category product design. The independent 38-member jury announced on 30 March that it awards the company with an “Honourable Mention” and acknowledges the well-executed design achievement of the FXS Combi. The filling and closing machine for pre-sterilized nested syringes, vials and cartridges (small glass containers), developed at the site in Crailsheim, is the first machine from the Packaging Technology division to receive this important design award.
“We are very happy about the Red Dot Award, which underlines our expertise in the development of innovative solutions for the pharmaceutical industry. The award shows that our products are not only convincing in terms of quality. They also stand out internationally because of their design,” says Klaus Ullherr, product manager at Bosch in Crailsheim. The international experts assessed a total of 4 928 entries from 56 countries. On June 29, the internationally renowned product competition will culminate in the Red Dot gala.
Flexibility for Various Packaging Types
The FXS Combi, which was launched at Interpack 2014, offers particular flexibility and safety. The machine is suited for three different pre-sterilized packaging types, as well as all common filling technologies. As the first filling and closing machine of this kind, the FXS Combi features an integrated capping station for vials and cartridges. Here, the containers are immediately closed after filling to ensure the highest pharmaceutical safety. By combining the machine with proven tub and bag openers, as well as different barrier systems, the FXS Combi can be flexibly integrated into complete line concepts, while allowing for significant space savings. Visitors to Achema 2015 can see for themselves in Frankfurt/Main, Germany, 15–19 June (hall 3.1, booth C71).
The Red Dot Award
The Red Dot Award was created by the Design Zentrum Nordrhein-Westfalen and is one of the best-respected design competitions in the world with approximately 17 000 entries each year. In 2015, the award is celebrating its 60th anniversary. In 1955, a jury convened for the first time to assess the best designs of the time. Today it consists of 38 members. The sought-after award, the “Red Dot”, is the internationally respected seal for outstanding design quality.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance